CRISPR Therapeutics AG. (10/4/17). "Press Release: CRISPR Therapeutics to Present at Investor Conferences in October". Zug & Cambridge, MA.

	Region	New York, NY
	Country	United States (USA)
	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Organisation 2	Jefferies LLC
	Group	Leucadia (Group)
	Product	Chardan Gene Therapy Conference 2017 New York
	Index term	CRISPR Therapeutics–Leucadia: investor conference, 201710 supply service CRISPR presents at Jefferies Gene Technology Investor Summit in New York
	Index term 2	CRISPR Therapeutics–Chardan: investor conference, 201710 supply service CRISPR presents at Chardan Gene Therapy Conference in New York
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Brinzey, Christopher F. (Chris) (Westwicke Partners 201703)

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President of CRISPR Therapeutics, is scheduled to present at two upcoming Investor Conferences in October.

Event: Chardan Gene Therapy Conference
Date: Tuesday, October 10, 2017
Time: 2:00 PM EDT

Event: Jefferies Gene Technology Investor Summit
Date: Thursday, October 12, 2017
Time: 11:10 AM EDT

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com

Record changed: 2023-06-05